开能健康(300272) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 was ¥424,707,970.27, a decrease of 4.74% compared to the same period last year[1]. - The net profit attributable to shareholders was ¥27,133,198.86, representing a significant decline of 64.08% year-over-year[1]. - The basic earnings per share decreased by 61.54% to ¥0.05, while diluted earnings per share fell by 69.23% to ¥0.04[1]. - Total operating revenue for Q3 2024 was CNY 1,254,037,408.51, a slight increase from CNY 1,241,561,388.15 in Q3 2023, representing a growth of approximately 1.2%[13]. - The net profit for Q3 2024 was CNY 109,643,066.89, a decrease of 26% compared to CNY 147,975,036.86 in the same period last year[14]. - Operating profit for the quarter was CNY 133,217,549.44, a decrease from CNY 152,273,327.70 year-over-year[14]. - The total profit for the quarter was CNY 132,289,380.05, down from CNY 151,561,262.28 in the same period last year[14]. - The company reported a total comprehensive income of CNY 107,145,756.59, compared to CNY 156,594,928.39 in the prior year[15]. - Basic earnings per share for the quarter were CNY 0.15, down from CNY 0.23 in the same quarter last year[15]. Cash Flow - Cash flow from operating activities for the period was ¥26,827,525.45, down 44.28% compared to the same period last year[1]. - The net cash flow from operating activities for Q3 2024 was approximately ¥212.82 million, a decrease of 26% compared to ¥287.49 million in Q3 2023[17]. - Total cash outflow from operating activities reached ¥1.12 billion, up from ¥1.02 billion in the same period last year, indicating a 9.5% increase[17]. - Cash inflow from financing activities totaled ¥841.13 million, a decrease from ¥885.78 million in Q3 2023[17]. - The net cash flow from financing activities was -¥113.08 million, contrasting with a positive cash flow of ¥325.46 million in the same quarter last year[17]. - The ending cash and cash equivalents balance was ¥912.04 million, down from ¥963.57 million at the end of Q3 2023[17]. Assets and Liabilities - The total assets at the end of the reporting period were ¥3,030,441,301.99, reflecting a 1.07% increase from the end of the previous year[1]. - Current assets totaled CNY 1,446,106,841.80, up from CNY 1,411,601,673.68, indicating a growth of about 2.4%[12]. - Non-current assets slightly decreased to CNY 1,584,334,460.19 from CNY 1,586,614,081.48, a decline of approximately 0.2%[12]. - Total liabilities increased to CNY 1,688,906,638.91 from CNY 1,627,081,011.90, representing a rise of about 3.8%[13]. - Shareholders' equity decreased to CNY 1,341,534,663.08 from CNY 1,371,134,743.26, a decline of approximately 2.2%[13]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 25,769[8]. - The largest shareholder, Qu Jianguo, holds 33.72% of the shares, amounting to 145,978,657 shares, which are pledged[8]. - The company has no new restricted shares added during the reporting period, maintaining a total of 145,978,657 restricted shares held by Qu Jianguo[10]. - The total number of shares held by the top 10 shareholders represents a significant portion of the company's equity, with the top shareholder alone holding over 33%[8]. - The company has not reported any changes in the status of shares due to lending or borrowing activities among the top shareholders[9]. Other Income and Expenses - The company reported a significant increase in other income, which rose by 65.36% to ¥6,851,813.30, mainly due to increased government subsidies[6]. - Investment losses amounted to ¥14,765,202.52, a 125.59% increase compared to the previous year, primarily from losses in associated companies[6]. - The company incurred financial expenses of CNY 11,265,300.04, compared to CNY 10,719,374.96 in the previous year[14]. - Research and development expenses amounted to CNY 46,343,257.83, slightly down from CNY 46,709,367.04 in the previous year[14]. - Tax payments amounted to ¥44.92 million, compared to ¥36.48 million in the same quarter last year, reflecting a 23% increase[17]. Inventory and Receivables - Inventory increased to CNY 262,154,033.48 from CNY 248,716,218.04, marking an increase of approximately 5.4%[12]. - Accounts receivable decreased to ¥205,975,541.84 from ¥213,633,280.29[11].